Key result
Trandolapril significantly reduces overall and cardiovascular mortality in post-MI patients with LV dysfunction.
Why the study?
Does trandolapril reduce mortality and severe heart failure in patients with reduced left ventricular function after myocardial infarction?
RCT
Randomized
Does trandolapril reduce mortality and severe heart failure in patients with reduced left ventricular function after myocardial infarction?
Long-term treatment with trandolapril significantly reduces mortality and the development of severe heart failure in patients with left ventricular dysfunction after myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports long-term ACE inhibitor use post-MI with LV dysfunction; confirms mortality and severe HF prevention in RCT.
Long-term treatment with trandolapril in patients with reduced left ventricular function soon after myocardial infarction significantly reduced the risk of overall mortality, mortality from cardiovascular causes, sudden death, and the development of severe heart failure. That mortality was reduced in a randomized study enrolling 25 percent of consecutive patients screened should encourage the selective use of ACE inhibition after myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Køber et al. (1995) conducted an RCT in Left ventricular dysfunction after myocardial infarction. Trandolapril was evaluated on Overall mortality. Long-term trandolapril in post-MI patients with LV dysfunction reduced overall mortality, CV mortality, sudden death, and severe heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: